



IFW

**PATENT**  
**Present Attorney Docket No. 05237.0003.CPUS01**


**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): LINK *et al.*  
App. No.: 10/660,893  
Filing Date: September 12, 2003  
Title: METHODS AND COMPOSITIONS  
FOR ELUCIDATING PROTEIN  
EXPRESSION PROFILES IN CELLS  
Art Unit: 1645  
Examiner: Not Yet Assigned

**CERTIFICATE OF MAILING**

I hereby certify that this paper is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

06/30/04  
Date

  
David W. Clough, Ph.D.  
Registration No. 36,107  
Attorney for Applicant

**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 and 1.98**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, Applicant calls to the attention of the Examiner references listed on the attached Forms PTO/SB/08A and PTO/SB/08B.

This Information Disclosure Statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes art under 35 U.S.C. §102 or §103.

The references listed on the Information Disclosure Statement were submitted and considered during prosecution of the parent application 09/811,842 from which the instant application is a continuation-in-part. Therefore, in compliance with 37 C.F.R. § 1.98(d)(1), Applicant does not submit copies for the listed references.

Attorney for Applicant also submits herewith a copy of the European Search Report dated April 2, 2004 and references cited in the report.

This Information Disclosure Statement is submitted, pursuant to 37 C.F.R. § 1.97 (b), prior to the examination on the merits of the above-identified patent application. Therefore, no fee is believed to be due with the submission. However, should any fees be deemed necessary in

connection with the prosecution of the above-identified patent application, the Commissioner is hereby authorized to deduct any such fees from our Deposit Account No. 08-3038.

Respectfully submitted,

HOWREY SIMON ARNOLD & WHITE, LLP


By: 

David W. Clough, Ph.D.

Registration No.: 36,107

Date: June 30, 2004

Howrey Simon Arnold & White, LLP  
321 N. Clark Street, Suite 3400  
Chicago, Illinois 60610  
Tel: (312) 595-1408  
Fax: (312) 595-2250



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>		
				<b>Application Number</b>	10/660,893	
				<b>Filing Date</b>	September 12, 2003	
				<b>First Named Inventor</b>	Charles Link	
				<b>Group Art Unit</b>	1645	
				<b>Examiner Name</b>	Not Yet Assigned	
<b>Attorney Docket Number</b>	05237.0003.CPUS01					
Sheet	1	of	5			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code <sup>2</sup> (if known)			
	A1	US-4,683,195	07-28-1987	Mullis	
	A2	US-5,364,783	11-15-1994	Ruley	
	A3	US-5,565,350	05-05-1998	Kmiec et al.	
	A4	US-5,922,601	07-13-1999	Baetscher	
	A5	US-6,130,313	10-10-2000	Li	
	A6	US-5,928,888	07-27-1999	Whitney	
	A7	2002/0025940 A1	02-28-2002	Whitney	
	A8	US-6,096,717	08-01-2000	Jarvik	
	A9	US-6,498,013 B1	12-24-2002	Velculescu	
	A10	US-6,080,576	06-27-2000	Zambrowicz	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> – Number <sup>4</sup> – Kind Code <sup>5</sup> (if known)				
	B1	WO 98/53319	11-26-98	Vogelstein		
	B2	WO 99/02719	01-21-99	Christopher		
	B3	WO 0056874 A	00-03-25	Massachusetts Institute of Technology		

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds codes of USPTO Patent Documents as [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/660,893
				<b>Filing Date</b>	September 12, 2003
				<b>First Named Inventor</b>	Charles Link
				<b>Group Art Unit</b>	1645
				<b>Examiner Name</b>	Yet to Be Assigned
Sheet	2	of	5	<b>Attorney Docket Number</b>	05237.0003.CPUS01

<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T <sup>2</sup>
	C1	Altschul et al. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. <b>Nucleic Acids Res.</b> 25: 3389-3402	
	C2	Armentano et al. (1987). Effect of Internal Viral Sequences on the Utility of Retroviral Vectors. <b>J. Virol.</b> 61: 1647-1650	
	C3	Bender et al. (1987). Evidence that the Packaging Signal of Moloney Murine Leukemia Virus Extends into the gag Region. <b>J. Virol.</b> 61: 1639-1649	
	C4	Claverie and States (1993). Information Enhancement Methods for Large Scale Sequence Analysis. <b>Comput. Chem.</b> 17: 191-201	
	C5	Cormier et al. (1974). Bioluminescence in Coelenterates. <b>Biochem. Biophys. Acta</b> 346: 137-164	
	C6	Corpet et al. (1988). Multiple Sequence Alignment with Hierarchical Clustering. <b>Nucleic Acid Res.</b> 16: 10881-90	
	C7	Costa et al. (1998). Transcriptional regulation of the tissue-type plasminogen activator gene in human endothelial cells: identification of nuclear factors that recognize functional elements in the tissue-type plasminogen activator gene promoter. <b>European Journal of Biochemistry</b> 258: 123-131	
	C8	Henikoff and Henikoff (1992). Amino acid Substitution Matrices From Protein Blocks. <b>Proc. Natl. Acad. Sci. USA</b> 89: 10915	
	C9	Higgins and Sharp (1988). Clustal: a package for performing multiple sequence alignment on a microcomputer. <b>Gene</b> 73: 237-244	
	C10	Higgins and Sharp (1989). Fast and sensitive multiple sequence alignments on a microcomputer. <b>CABIOS</b> 5: 151-153	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>	10/660,893
				<b>Filing Date</b>	September 12, 2003
				<b>First Named Inventor</b>	Charles Link
				<b>Group Art Unit</b>	1645
				<b>Examiner Name</b>	Yet to Be Assigned
Sheet	3	of	5	<b>Attorney Docket Number</b>	05237.0003.CPUS01

	C11	The human gene consortium. (2001). Initial sequencing and analysis of the human genome. <b>Nature</b> 409: 860-921	
	C12	Huang et al. (1992). Parallelization of a local similarity algorithm. <b>Computer Applications in the Biosciences</b> 8: 155-65	
	C13	Fassati et al. (1998). Insertion of Two Independent Enhancers in the Long Terminal Repeat of a Self Inactivating Vector Results in High-Titer Retroviral Vectors With Tissue Specific Expression. <b>Human Gene Therapy</b> 9: 2459-2468	
	C14	Fleischmann et al. (1998). Cardiac Specific Expression of the Green Fluorescent Protein During Early Murine Embryonic Development. <b>FEBS Letters</b> 440: 370-376	
	C15	Fraser et al. (1997). Strategies for whole microbial genome sequencing and analysis. <b>Electrophoresis</b> 18: 1207-1216	
	C16	Goeddel et al. (1980). <b>Nucleic Acid Res.</b> 8: 4057	
	C17	Gygi et al. (1999). Correlation between protein and mRNA abundance in yeast. <b>Molecular and Cellular Biology</b> : 1720-1720	
	C18	Larison et al. (1995). Use of a New Fluorogenic Phosphatase Substrate in Immunohistochemical Applications. <b>J. Histochem. Cytochem.</b> 43: 77-83	
	C19	Lidberg et al. (1998). Transcriptional Regulation of Human Carboxyl Ester Lipase Gene in Exocrine Pancreas. <b>The Journal of Biological Chemistry</b> 273: 47	
	C20	Meyers and Miller (1988). Optimal alignments in linear space. <b>Computer Applic. Biol. Sci.</b> 4: 11-17	
	C21	Miller et al. (1989). Improved retroviral vectors for gene transfer and expression. <b>Biotechniques</b> 7: 980-990	
	C22	Needleman and Wunsch (1970). A general method applicable to the search for similarities in the amino acid sequence of two proteins. <b>J. Mol. Biol.</b> 48: 443	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/660,893
				<b>Filing Date</b>	September 12, 2003
				<b>First Named Inventor</b>	Charles Link
				<b>Group Art Unit</b>	1645
				<b>Examiner Name</b>	Yet to Be Assigned
<b>Sheet</b>	4	<b>of</b>	5	<b>Attorney Docket Number</b>	05237.0003.CPUS01

	C23	Paulus et al. (1996). Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. <b>J. of Virology</b> 70: 62-67	
	C24	Pearson and Lipman (1988). Improved tools for biological sequence comparison. <b>Proc. Natl. Acad. Sci.</b> 85: 2444	
	C25	Person et al. (1994). Using the FAFSA program to search protein and DNA sequence databases. <b>Methods in Molecular Biology</b> 24: 307-331	
	C26	Post et al. (1981). Regulation of $\alpha$ genes of herpes simplex virus: expression of chimeric genes produced by fusion of thymidine kinase with $\alpha$ gene promoters. <b>Cell</b> 24: 555-565	
	C27	Smith and Waterman (1981). Comparison of biosequences. <b>Adv. Appl. Math.</b> 2: 482	
	C28	Shimatake et al. (1981). Purified $\chi$ regulatory protein CII positively activates promoters for lysogenic development. <b>Nature</b> 292: 128	
	C29	Igarashi et. al. (1998). A Novel Strategy of Cell Targeting Based on Tissue-Specific Expression of the Ecotopic Retrovirus Expression Gene. <b>Human Gene Therapy</b> 9: 2691-2698	
	C30	Valerie et al. (1998). Tissue Specific Cell Cycle Regulated Chimeric Transcription Factors for the Targeting of Gene Expression to Tumor Cells. <b>Human Gene Therapy</b> 9: 2653-2659	
	C31	Medico et al (2001). A gene trap vector system for identifying transcriptionally responsive genes. <b>Nature Biotech.</b> 19: 579.	
	C32	Wooten and Federhen (1993). <b>Comput. Chem.</b> 17: 149-163	
	C33	Young and Link (2000). Chimeric Retroviral Helper Virus and Picornavirus IRES Sequence to Eliminate DNA Methylation for Improved Retroviral Packaging Cells. <b>J. Virol.</b> 74(11): 5242-5249	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>	10/660,893
				<b>Filing Date</b>	September 12, 2003
				<b>First Named Inventor</b>	Charles Link
				<b>Group Art Unit</b>	1645
				<b>Examiner Name</b>	Yet to Be Assigned
<b>Sheet</b>	5	<b>of</b>	5	<b>Attorney Docket Number</b>	05237.0003.CPUS01

C34	Yu et al (1998). Coregulation of Tissue-Specific Alternative Human Carnitine Palmitoyltransferase IB Gene Promoter by Fatty Acid Enzyme Substrate. <b>The Journal of Biological Chemistry</b> 273, No. 49	
C35	Whitney et al (1998) A genome-wide functional assay of signal transduction in living mammalian cells. <b>Nature Biotechnology</b> 16:1329	
C36	Jarvik et al (1996). CD-Tagging: A new approach to gene and protein discovery and analysis. <b>BioTechniques</b> 20: 896-904	
C37	Skarnes et al (1995). Capturing genes encoding membrane and secreted proteins important for mouse development. <b>Proc. Natl. Acad. Sci USA</b> 92: 6592	
C38	Zambrowicz et al (1998). Disruption and sequence identification of 2000 genes in mouse embryonic stem cells. <b>Nature</b> 392: 608-611.	
C39	European Search Report, dated April 2, 2004	
C40	Brenner, et al. (1989). Analysis of mammalian cell genetic regulation in situ by using retrovirus-derived 'portable exons' carrying the Escherichia coli lacZ gene," <b>Proc. Natl. Acad. Sci</b> , Vol. 86, No 14, pages 5517-5521	
C41	Stanford et al. (1998). Expression Trapping: Identification of Novel Genes Expressed in Hematopoietic and Endothelial Lineages by Gene Trapping in ES cells. <b>Blood</b> , Vol. 92, No. 12, pages 4622 to 4631.	
C42	Kerr et al. (1996). Analysis of lipopolysaccharide-response genes in B-lineage cells demonstrates that they can have differentiation stage-restricted expression and contain SN2 domains. <b>Proc. Natl. Acad. Sci. Vol. 93, No. 9, pages 3947-3952.</b>	
C43	Tate et al. (1998). Capturing novel mouse genes encoding chromosomal and other nuclear proteins. <b>J. Cell. Science</b> , Vol. 111, pages 2575-2585.	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/660,893
				<b>Filing Date</b>	September 12, 2003
				<b>First Named Inventor</b>	Charles Link
				<b>Group Art Unit</b>	1645
				<b>Examiner Name</b>	Yet to Be Assigned
Sheet	6	of	5	<b>Attorney Docket Number</b>	05237.0003.CPUS01

	C44	Suarez, et al. (1997). Green fluorescent protein-based reporter systems for genetic analysis of bacteria including monocopy applications. <b>Gene</b> , Vol. 196, Nos. 1-2, pages 69-74.	
--	-----	--	--

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.